Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20776
Title: Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
Austin Authors: Ma, Henry;Campbell, Bruce C V;Parsons, Mark W;Churilov, Leonid ;Levi, Christopher R;Hsu, Chung;Kleinig, Timothy J;Wijeratne, Tissa;Curtze, Sami;Dewey, Helen M;Miteff, Ferdinand;Tsai, Chon-Haw;Lee, Jiunn-Tay;Phan, Thanh G;Mahant, Neil;Sun, Mu-Chien;Krause, Martin;Sturm, Jonathan;Grimley, Rohan;Chen, Chih-Hung;Hu, Chaur-Jong;Wong, Andrew A;Field, Deborah;Sun, Yu;Barber, P Alan;Sabet, Arman;Jannes, Jim;Jeng, Jiann-Shing;Clissold, Benjamin;Markus, Romesh;Lin, Ching-Huang;Lien, Li-Ming;Bladin, Christopher F;Christensen, Søren;Yassi, Nawaf;Sharma, Gagan;Bivard, Andrew;Desmond, Patricia M;Yan, Bernard;Mitchell, Peter J;Thijs, Vincent N ;Carey, Leeanne;Meretoja, Atte;Davis, Stephen M;Donnan, Geoffrey A 
Affiliation: Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora, Victoria, Australia
Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital, University of Newcastle , Newcastle, Australia
Department of Neurology, Westmead Hospital , the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney , and the Department of Neurology, St. Vincent's Hospital Sydney , Sydney, Australia
Department of Neurology, Gosford Hospital, Gosford , NSW,, Australia
Department of Neurology, Royal Adelaide Hospital, the Department of Neurology, Lyell McEwin Hospital , and the Department of Neurology, Queen Elizabeth Hospital , Adelaide, SA, Australia
Department of Medicine, Sunshine Coast University Hospital, Nambour, Australia
Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane, Australia
Florey Institute of Neuroscience and Mental Health, the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, Victoria, Australia
Department of Radiology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
Department of Medicine, School of Clinical Science, Monash University, Clayton, Victoria, Australia
Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans, Victoria, Australia
Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia
Department of Neurology, University Hospital Geelong, Deakin University, Geelong, Victoria, Australia
Stanford Stroke Center, Stanford University, Stanford, CA
ersity Hospital, Southport, and Australia and Griffith University, Gold Coast, QLD, Australia
Graduate Institute of Clinical Medical Science and the School of Medicine, China Medical University, Taichung, Taiwan
Department of Neurology, China Medical University Hospital, Taichung, Taiwan
Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, the Department of Neurology, Shuang Ho Hospital, the Department of Neurology, En Chu Kong Hospital, the Stroke Center and Department of Neurology, National Taiwan University Hospital, and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine, Taipei, Taiwan
Department of Neurology, Gold Coast UnivDepartment of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Department of Neurology, Helsinki University Hospital, Helsinki
Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand
Issue Date: 9-May-2019
Publication information: The New England Journal of Medicine 2019; 380(19): 1795-1803
Abstract: The time to initiate intravenous thrombolysis for acute ischemic stroke is generally limited to within 4.5 hours after the onset of symptoms. Some trials have suggested that the treatment window may be extended in patients who are shown to have ischemic but not yet infarcted brain tissue on imaging. We conducted a multicenter, randomized, placebo-controlled trial involving patients with ischemic stroke who had hypoperfused but salvageable regions of brain detected on automated perfusion imaging. The patients were randomly assigned to receive intravenous alteplase or placebo between 4.5 and 9.0 hours after the onset of stroke or on awakening with stroke (if within 9 hours from the midpoint of sleep). The primary outcome was a score of 0 or 1 on the modified Rankin scale, on which scores range from 0 (no symptoms) to 6 (death), at 90 days. The risk ratio for the primary outcome was adjusted for age and clinical severity at baseline. After 225 of the planned 310 patients had been enrolled, the trial was terminated because of a loss of equipoise after the publication of positive results from a previous trial. A total of 113 patients were randomly assigned to the alteplase group and 112 to the placebo group. The primary outcome occurred in 40 patients (35.4%) in the alteplase group and in 33 patients (29.5%) in the placebo group (adjusted risk ratio, 1.44; 95% confidence interval [CI], 1.01 to 2.06; P = 0.04). Symptomatic intracerebral hemorrhage occurred in 7 patients (6.2%) in the alteplase group and in 1 patient (0.9%) in the placebo group (adjusted risk ratio, 7.22; 95% CI, 0.97 to 53.5; P = 0.05). A secondary ordinal analysis of the distribution of scores on the modified Rankin scale did not show a significant between-group difference in functional improvement at 90 days. Among the patients in this trial who had ischemic stroke and salvageable brain tissue, the use of alteplase between 4.5 and 9.0 hours after stroke onset or at the time the patient awoke with stroke symptoms resulted in a higher percentage of patients with no or minor neurologic deficits than the use of placebo. There were more cases of symptomatic cerebral hemorrhage in the alteplase group than in the placebo group. (Funded by the Australian National Health and Medical Research Council and others; EXTEND ClinicalTrials.gov numbers, NCT00887328 and NCT01580839.).
URI: http://ahro.austin.org.au/austinjspui/handle/1/20776
DOI: 10.1056/NEJMoa1813046
ORCID: 0000-0002-0510-8059
0000-0003-3632-9433
0000-0002-6614-8417
PubMed URL: 31067369
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Feb 24, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.